Nerviano Medical Sciences signs research agreement with Università del Piemonte Orientale, Faculty of Pharmaceutical Sciences
NMS Group
June 28, 2022

Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of Pharmaceutical Sciences in Novara (DSF), as part of the National Operational Programme on Research and Innovation 2014-2020 (Programma Operativo Nazionale (PON) – “RICERCA E INNOVAZIONE” 2014-2020). The Programme is the key instrument with which the Italian government contributes to the improvement of the quality of higher education and the enhancement of research, technological development and innovation.

The agreement signed under the “Accordo Università / Imprese” of the programme, echoes perfectly the government’s intention to foster the development of new professional skills required in the labor market and training high profile professionals. We will bring in two PhD students for a semester in 2023 in the NMS laboratories of the Medicinal Chemistry & Drug Design Department, to advance shared research programs, both approved by the Italian Ministry of University and Research on “Innovation and Green” subjects.

The scientific supervisors from the DSF are:

Professor Tracey Pirali, Associate Professor of Medicinal Chemistry. An expert in the use of deuterium in medicinal chemistry, Professor Pirali has co-founded the ChemIcare startup as a spin-off of the DSF, which recently received the EMA orphan drug designation for their drug candidate CIC-39 targeting the Store-Operated Calcium Entry (SOCE). The shared research programs that Professor Pirali leads will be focused on the discovery of innovative synthetic strategies to streamline the access to biologically active compounds.

Professor Gian Cesare Tron, Full Professor of Medicinal Chemistry. A worldwide recognized expert in multicomponent reactions, Professor Tron is the inventor of the split-Ugi reaction and developed inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) enzyme. The shared research program that Professor Tron leads will be focused on the improvement or the invention of novel and mild procedures for isocyanides synthesis, using green reagents and methodologies (such as multicomponent reactions, micellar catalysis, electrosynthesis, and click chemistry).

The scientific supervisor from NMS is Gianluca Papeo, Group Leader and Project Leader in the Medicinal Chemistry & Drug Design Department.

“We are delighted that the faculty of Pharmaceutical Sciences of Università del Piemonte Orientale has joined forces with us to develop our shared research programs in NMS labs. The exchange and collaboration between academia and private companies is vital to keep our scientists exposed to fresh ideas and we believe that we can equip the students with specific skills to be competitive in the future and retain talents in the pole of oncology excellency in Italy,” said Antonella Isacchi, CSO of NMS.

“Collaborations with solid partners like NMS help DSF to achieve enduring excellence in research and education for the benefit of society. Our collaboration with NMS is enhanced by DSF’s strong academic foundations in innovative synthetic strategies and multicomponent reaction research. We look forward to the result of our fruitful collaboration through our talents,” commented Professor Tracey Pirali and Professor Gian Cesare Tron of DSF.

20220627-Università del Piemonte Orientale-Final

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO